Sutezolid Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sutezolid Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Phase 2/3
Highest phase
8
Registered trials
4
Result records
1
Matched deals
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Sutezolid can convert its Small molecule drug profile and 50S subunit biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sutezolid (query alias: sutezolid) |
|---|---|
| Modality / target | Small molecule drug; 50S subunit; 50S subunit inhibitors |
| Highest global status | Phase 2/3 |
| Originator | Pfizer Inc. |
| Active developers | Global Alliance for TB Drug Development, Sequella, Inc., Pfizer Inc. |
The MCP disease footprint includes Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05686356 | Phase 2/3 | Active, not recruiting | 352 | The proportion of patients achieving durable (non-relapsing) cure |
| NCT06192160 | Phase 2 | Recruiting | 315 | Difference in mean log10 (Time to positivity (TTP)) slope from longitudinal mycobacteria growth indicator tube (MGIT) liquid culture measurements over the first 6 weeks of treatment |
| NCT05971602 | Phase 2 | Terminated | 93 | Percentage of Participants With DS-TB Reporting ≥ Grade 3 Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis
Phase 2; n=93; evaluation: not stated. Reported fields: -; ≥ Grade 3 TEAEs At Week 19 = 16.7 percentage of participants ; -
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe
Phase 2; n=94; evaluation: Positive. Reported fields: AE = The most common AEs were gastrointestinal, and the most common SAEs were related to the nervous and gastrointestinal systems. There were no deaths reported during the study. ; AE = The most common AEs were gastrointestinal, and the most common SAEs were related to the nervous and gastrointestinal systems. There were no deaths reported during the study.
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
Phase 2; n=75; evaluation: Positive. Reported fields: Adverse Event: hepatotoxicity = grade 4 adverse event in the Sutezolid 800 mg twice daily group ; Adverse Event: hepatotoxicity = grade 4 adverse event in the Sutezolid 800 mg twice daily group
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sutezolid addresses Pulmonary Tuberculosis, Tuberculosis, Multidrug-Resistant. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2013-07-17 | Sequella Acquires Exclusive Worldwide Rights to Pfizer’s Sutezolid, Currently in Clinical Development for Tuberculosis | Phase 2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Application of sutezolid (PNU-100480) to mycobacterium avium composite flora infection”. The milestone feed surfaced a patent-application signal described as “An improved process for the preparation of sutezolid”. The milestone feed surfaced a patent-application signal described as “A novel process for the preparation of sutezolid”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
